Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database

CHIEN-CHANG LEEHsu, Tzu-ChunTzu-ChunHsuKuo, Chia-ChihChia-ChihKuoLiu, Michael AMichael ALiuAbdelfattah, Ahmed MAhmed MAbdelfattahChang, Chia-NaChia-NaChangMING YAOLi, Chi-ChengChi-ChengLiWu, Kang-HsiKang-HsiWuChen, Tsung-ChihTsung-ChihChenGau, Jyh-PyngJyh-PyngGauWang, Po-NanPo-NanWangLiu, Yi-ChangYi-ChangLiuChiou, Lun-WeiLun-WeiChiouLee, Ming-YangMing-YangLeeLi, Sin-SyueSin-SyueLiChao, Tsu-YiTsu-YiChaoSHIANN-TANG JOUHSIU-HAO CHANG2021-10-292021-10-292021-09-1010837159https://scholars.lib.ntu.edu.tw/handle/123456789/586015We externally validated Fujimoto's post-transplant lymphoproliferative disorder (PTLD) scoring system for risk prediction by using the Taiwan Blood and Marrow Transplant Registry Database (TBMTRD) and aimed to create a superior scoring system using machine learning methods.enHematopoietic cell transplant; Least absolute shrinkage and selection operator; Post-transplant lymphoproliferative disorder; Predictive scoring system[SDGs]SDG3[SDGs]SDG16busulfan; cyclophosphamide; fludarabine; thymocyte antibody; acute lymphoblastic leukemia; acute myeloid leukemia; adult; aplastic anemia; Article; bone marrow transplantation; chronic lymphatic leukemia; chronic myeloid leukemia; coronary artery bypass graft; demography; diagnostic procedure; female; graft versus host reaction; hematologic disease; hematopoietic stem cell transplantation; hematopoietic system malignancy; Hodgkin disease; human; human cell; human experiment; immunosuppressive treatment; laboratory test; major clinical study; male; multiple myeloma; myelodysplastic syndrome; myeloproliferative disorder; nonhodgkin lymphoma; patient registry; peripheral blood stem cell; posttransplant lymphoproliferative disease; prediction; prospective study; pulmonary veno-occlusive disease; receiver operating characteristic; risk assessment; scoring system; sensitivity and specificity; survival; thalassemia major; umbilical cord blood; validation study; adverse event; hematopoietic stem cell transplantation; lymphoproliferative disease; methodology; register; risk factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Registries; Research Design; Risk FactorsValidation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Databasejournal article10.1002/onco.13969345066882-s2.0-85115353952https://api.elsevier.com/content/abstract/scopus_id/85115353952